# EDGAR Filing Document

**Accession Number:** 0000839087
**File Stem:** 0001213900-25-123593
**Filing Date:** 2025-12
**Character Count:** 7233
**Document Hash:** 07909d9257ed341634f4abdf7897a9fd
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-25-123593.hdr.sgml**: 20251219

**ACCESSION NUMBER**: 0001213900-25-123593

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 12

**CONFORMED PERIOD OF REPORT**: 20251217

**ITEM INFORMATION**: Submission of Matters to a Vote of Security Holders

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20251219

**DATE AS OF CHANGE**: 20251219

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** VASO Corp
- **CENTRAL INDEX KEY:** 0000839087
- **STANDARD INDUSTRIAL CLASSIFICATION:** ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 112871434
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 000-18105
- **FILM NUMBER:** 251585991

**BUSINESS ADDRESS:**
- **STREET 1:** 137 COMMERCIAL STREET, STE. 200
- **CITY:** PLAINVIEW
- **STATE:** NY
- **ZIP:** 11803
- **BUSINESS PHONE:** 516-997-4600

**MAIL ADDRESS:**
- **STREET 1:** 137 COMMERCIAL STREET, STE. 200
- **CITY:** PLAINVIEW
- **STATE:** NY
- **ZIP:** 11803

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** VASOMEDICAL, INC
- **DATE OF NAME CHANGE:** 20120606

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** VASOMEDICAL INC
- **DATE OF NAME CHANGE:** 19950517

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** FUTURE MEDICAL PRODUCTS INC /DE/
- **DATE OF NAME CHANGE:** 19920703

?xml version='1.0' encoding='ASCII'?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, DC 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): <u>December 17, 2025</u>

**VASO CORPORATION**

**(Exact Name of Registrant as Specified in Charter)**

---

| | | |
|:---|:---|:---|
| Delaware | 0-18105 | 11-2871434 |
| **(State or Other Jurisdiction<br> of Incorporation)** | **(Commission File Number)** | **(I.R.S. Employer<br> Identification No.)** |

---

---

| |
|:---|
| 137 Commercial St., Suite 200, Plainview, New York 11803 |
| **(Address of Principal Executive Offices and Zip Code)** |
| (516) 997-4600 |
| **Registrant's Telephone Number, Including Area Code** |
| Not Applicable |
| **(Former Name or Former Address, if Changed Since Last Report)** |

---

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of Each Class** | **Trading Symbol(s)** | **Name of Each Exchange on which Registered** |

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

☐ Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Exchange Act (17 CFR §240.12b-2).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

---

| | |
|:---|:---|
| **Item 5.07** | **Submission of Matters to a Vote of Security Holders.** |

---

Vaso Corporation (the "**Company**") held its Annual Meeting of Shareholders (the "Annual Meeting") on December 17, 2025. At the Annual Meeting, the Company's shareholders were asked to vote on the following three matters: (1) Election of three Class II directors, to serve for a three-year term and until their successors are elected and qualify; (2) approval of a non-binding "Say on Pay" proposal to approve the compensation of the Company's named executive officers (a so-called "**Say on Pay**" vote); and (3) approval of a non-binding proposal for stockholders to recommend to the Board of Directors the frequency at which the Company should hold a non-binding Say on Pay vote (a so-called "**Say When on Pay**" vote).

As of the record date for the meeting, there were 175,953,035 outstanding shares of common stock entitled to vote. A total of 120,208,576 shares of common stock were voted at the Annual Meeting either in person or by proxy.

The following is a summary of the final voting results for the matters presented to the shareholders:

***<u>Proposal 1 – Election of Directors</u>***. The following three director nominees were elected to serve for a three-year term.

---

| | | | |
|:---|:---|:---|:---|
| **Nominee** | **For** | **Withheld** | **Broker non-Votes** |
| Behnam Movaseghi | 103664162 | 16544414 | N/A |
| Jane Moen | 109424726 | 10783850 | N/A |
| Leon Dembo | 103581987 | 16626589 | N/A |

---

***<u>Proposal 2 – Advisory Say on Pay Vote</u>***. The non-binding advisory proposal to approve the compensation of the Company's named executive officers was approved. The voting results were as follows:

---

| | | | |
|:---|:---|:---|:---|
| **For** | **Against** | **Abstain** | **Broker non-Votes** |
| 105612284 | 12759718 | 1836574 | &nbsp;&nbsp;&nbsp;&nbsp;N/A |

---

***<u>Proposal 3 – Advisory Say When on Pay Vote</u>***. The shareholders approved in a non-binding advisory vote to recommend that a "Say on Pay" vote be presented to shareholders every three years. The voting results were as follows:

---

| | | | |
|:---|:---|:---|:---|
| **One Year** | **Two Years** | **Three Years** | **Abstentions** |
| 16828312 | 1975106 | 97734812 | 3670346 |

---

Holders of approximately 56% of the outstanding shares voted in favor of offering future Say on Pay votes to the Corporation's shareholders every three years, which was also management's recommendation. In light of the shareholders vote, and upon the recommendation of its Nominating and Corporate Governance Committee, the Board of Directors determined that future Say on Pay votes will be presented to the shareholders every three years. Thus, the next shareholder Say on Pay vote will be presented to the shareholders at the Corporation's 2028 annual meeting.

---

| | |
|:---|:---|
| **Item 9.01** | **Exhibits** |

---

---

| | |
|:---|:---|
| **Exhibit No.** | **Description** |
| 104 | Cover page Interactive Data File (the cover page XBRL tags are embedded within the Inline XBRL document) |

---

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: December 19, 2025

---

| | |
|:---|:---|
| **VASO CORPORATION** | **VASO CORPORATION** |
| By: | /s/ Jun Ma |
| Name: | Jun Ma |
| Title: | Chief Executive Officer and President |

---